Remote Monitoring ROI MTI’s GoSpiro home spirometer and MTI CarePortal enable scalable in home remote monitoring for COPD, asthma, lung transplant, and cystic fibrosis. The FDA cleared GoSpiro provides lab quality results at home, offering health systems and payers a path to reduce hospital admissions, improve drug adherence, and lower cost of care.

Strategic Partnerships Capitalizing on MTI’s prior distribution with MGC Diagnostics and its cloud based platform, there is an opportunity to expand channel partnerships with clinics, hospitals, and telehealth networks to accelerate adoption in regional and national accounts.

Growth Readiness MTI has expanded facilities and headcount and operates with revenue in the one to ten million range backed by funding. This growth trajectory supports larger pilots and multi site deployments with health plans, IDNs, and home health providers.

Disease Focus The company targets COPD, asthma, lung transplant, and cystic fibrosis, aligning with payer and provider interest in chronic disease remote monitoring. There is cross sell potential for GoSpiro, GoHome, GoClinic, GoECG, and MTI CarePortal across patient populations and specialty clinics.

Cloud Enabled Platform A Google Cloud based platform with data analytics supports scalable remote care programs and interoperability with telehealth and electronic medical records, appealing to health systems seeking standardized workflows and outcomes data for value based contracts.